Brief: TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue and 2025 Anticipated Development Milestones
14/01/2025 12:43
Jan 14 (Reuters) - TG Therapeutics Inc TGTX.O :
* TG THERAPEUTICS PROVIDES PRELIMINARY FOURTH QUARTER AND
FULL
YEAR 2024 NET REVENUE AND 2025 ANTICIPATED DEVELOPMENT
MILESTONES
* QTRLY BRIUMVI U.S. NET PRODUCT REVENUE EXPECTED TO BE
$103.6
MILLION
* OUTLOOK FY 2025 TARGET TOTAL GLOBAL REVENUE OF ABOUT $540
MILLION
* FY2025 REVENUE VIEW $549.5 MILLION -- LSEG IBES DATA
Source text: ID:nGNXbRCsyr
Further company coverage: TGTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TG Therapeutics
See all newsTG Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tg Therapeutics Reports Second Quarter 2026 Financial Results And Raises Briumvi® Revenue Guidance
TG Therapeutics Q2 product revenue rises 70% on BRIUMVI sales
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj